UPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
B.Riley/FBR Starts Eiger BioPharma (EIGR) at Buy
May 9, 2018 9:30 AM EDTB.Riley/FBR initiates coverage on Eiger BioPharma (NASDAQ: EIGR) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Eiger BioPharma click here. For more ratings news on Eiger BioPharma click here.
Shares of Eiger BioPharma closed at $9.20 yesterday.
... More